In light of this preclinical evidence, our results provide support that IDH mutations in clonal hematopoiesis may play an essential role as a cardiovascular risk factor in driving cardiovascular disease progression, which should be taken into account especially prior to initiation of chemotherapy, because left ventricular dysfunction is a common side effect of cancer treatment [36]. The gene discussed is IDH1; the disease is cancer.